|
1
|
Ferreri AJ, Abrey LE, Blay JY, Borisch B,
Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J
and Batchelor T: Summary statement on primary central nervous
system lymphomas from the Eighth International Conference on
Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J
Clin Oncol. 21:2407–2414. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller DC, Hochberg FH, Harris NL, Gruber
ML, Louis DN and Cohen H: Pathology with clinical correlations of
primary central nervous system non-Hodgkin's lymphoma. The
Massachusetts General Hospital experience 1958–1989. Cancer.
74:1383–1397. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rubenstein JL, Hsi ED, Johnson JL, Jung
SH, Nakashima MO, Grant B, Cheson BD and Kaplan LD: Intensive
chemotherapy and immunotherapy in patients with newly diagnosed
primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol.
31:3061–3068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jang JE, Kim YR, Kim SJ, Cho H, Chung H,
Lee JY, Park H, Kim Y, Cheong JW, Min YH and Kim JS: A new
prognostic model using absolute lymphocyte count in patients with
primary central nervous system lymphoma. Eur J Cancer. 57:127–135.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Joerger M, Huitema AD, Krähenbühl S,
Schellens JH, Cerny T, Reni M, Zucca E, Cavalli F and Ferreri AJ:
Methotrexate area under the curve is an important outcome predictor
in patients with primary CNS lymphoma: A
pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20
trial. Br J Cancer. 102:673–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hottinger AF, Alentorn A and Hoang-Xuan K:
Recent developments and controversies in primary central nervous
system lymphoma. Curr Opin Oncol. 27:496–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoang-Xuan K, Bessell E, Bromberg J,
Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C,
Abacioglu U, et al: Diagnosis and treatment of primary CNS lymphoma
in immunocompetent patients: Guidelines from the European
Association for Neuro-Oncology. Lancet Oncol. 16:e322–e332. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan
RB, Panetta JC, Krull KR, Inaba H, Rubnitz JE, Metzger ML, et al:
Methotrexate-induced neurotoxicity and leukoencephalopathy in
childhood acute lymphoblastic leukemia. J Clin Oncol. 32:949–959.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cohen IJ: Neurotoxicity after high-dose
methotrexate (MTX) is adequately explained by insufficient folinic
acid rescue. Cancer Chemother Pharmacol. 79:1057–1065. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cher L, Glass J, Harsh GR and Hochberg FH:
Therapy of primary CNS lymphoma with methotrexate-based
chemotherapy and deferred radiotherapy: Preliminary results.
Neurology. 46:1757–1759. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guha-Thakurta N, Damek D, Pollack C and
Hochberg FH: Intravenous methotrexate as initial treatment for
primary central nervous system lymphoma: Response to therapy and
quality of life of patients. J Neurooncol. 43:259–268. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Citterio G, Reni M and Ferreri AJ: Present
and future treatment options for primary CNS lymphoma. Expert Opin
Pharmacother. 16:2569–2579. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferreri AJ, Reni M, Foppoli M, Martelli M,
Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G,
Ilariucci F, et al: High-dose cytarabine plus high-dose
methotrexate versus high-dose methotrexate alone in patients with
primary CNS lymphoma: A randomised phase 2 trial. Lancet.
374:1512–1520. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Crivellari D, Lombardi D, Spazzapan S,
Veronesi A and Toffoli G: New oral drugs in older patients: A
review of idarubicin in elderly patients. Crit Rev Oncol Hematol.
49:153–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Geffen DB and Man S: New drugs for the
treatment of cancer, 1990–2001. Isr Med Assoc J. 4:1124–1131.
2002.PubMed/NCBI
|
|
16
|
Xu G, Yang M, Tong H, Mao L and Jin J:
High-dose methotrexate plus temozolomide as a salvage treatment in
metastatic central nervous system Lymphoma: Two cases report and
review of literature. Int J Clin Exp Med. 8:8222–8225.
2015.PubMed/NCBI
|
|
17
|
Ferreri AJ, Cwynarski K, Pulczynski E, et
al: The addition of thiotepa and rituximab to antimetabolites
significantly improves outcome in primary CNS lymphoma: The first
randomization of the IELSG-32 trial. Int Conference Malignant
Lymphoma. 2015.
|
|
18
|
Ponzoni M, Issa S, Batchelor TT and
Rubenstein JL: Beyond high-dose methotrexate and brain
radiotherapy: Novel targets and agents for primary CNS lymphoma.
Ann Oncol. 25:316–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muggia FM: Teniposide: Overview of its
therapeutic potential in adult cancers. Cancer Chemother Pharmacol.
34 (Suppl):S127–S133. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fan N, Chen BB, Zhu C, Xu XP, Lin ZG, Ma Y
and Zhang J: Comparison of the efficacy of MTX-alone and combined
with other drugs in treating CNS DLBCL. Fudan Univ J Med Sci.
41:81–87. 2014.
|
|
21
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of
tumors of Hematopoietic and Lymphoid Tissues. IARC; Lyon: pp.
4392008
|
|
22
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Abrey LE, Batchelor TT, Ferreri AJ,
Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A,
Soussain C, DeAngelis LM, et al: Report of an international
workshop to standardize baseline evaluation and response criteria
for primary CNS lymphoma. J Clin Oncol. 23:5034–5043. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jellinger KA and Paulus W: Primary central
nervous system lymphomas-an update. J Cancer Res Clin Oncol.
119:7–27. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reni M, Ferreri AJ, Garancini MP and Villa
E: Therapeutic management of primary central nervous system
lymphoma in immunocompetent patients: Results of a critical review
of the literature. Ann Oncol. 8:227–234. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Michalski JM, Garcia DM, Kase E, Grigsby
PW and Simpson JR: Primary central nervous system lymphoma:
Analysis of prognostic variables and patterns of treatment failure.
Radiology. 176:855–860. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gerstner ER and Batchelor TT: Primary
central nervous system lymphoma. Arch Neurol. 67:291–297. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Low S and Batchelor TT: Primary central
nervous system lymphoma. Semin Neurol. 38:86–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haldorsen IS, Krossnes BK, Aarseth JH,
Scheie D, Johannesen TB, Mella O and Espeland A: Increasing
incidence and continued dismal outcome of primary central nervous
system lymphoma in Norway 1989–2003: Time trends in a 15-year
national survey. Cancer. 110:1803–1814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Makino K, Nakamura H, Kino T, Takeshima H
and Kuratsu J: Rising incidence of primary central nervous system
lymphoma in Kumamoto, Japan. Surg Neurol. 66:503–506. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eloranta S, Branvall E, Celsing F,
Papworth K, Ljungqvist M, Enblad G and Ekström-Smedby K: Increasing
incidence of primary central nervous system lymphoma but no
improvement in survival in Sweden 2000–2013. Eur J Haematol.
100:61–68. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bayraktar S, Bayraktar UD, Ramos JC,
Stefanovic A and Lossos IS: Primary CNS lymphoma in HIV positive
and negative patients: Comparison of clinical characteristics,
outcome and prognostic factors. J Neurooncol. 101:257–265. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferreri AJ, Blay JY, Reni M, Pasini F,
Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi
A, et al: Prognostic scoring system for primary CNS lymphomas: The
International Extranodal Lymphoma Study Group experience. J Clin
Oncol. 21:266–272. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bataille B, Delwail V, Menet E,
Vandermarcq P, Ingrand P, Wager M, Guy G and Lapierre F: Primary
intracerebral malignant lymphoma: Report of 248 cases. J Neurosurg.
92:261–266. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gelabert-González M, Castro Bouzas D,
Serramito-García R, Frieiro Dantas C and Aran Echabe E: Primary
central nervous system lymphoma. Neurologia. 28:283–293. 2013.(In
English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Deckert M, Engert A, Brück W, Ferreri AJ,
Finke J, Illerhaus G, Klapper W, Korfel A, Küppers R, Maarouf M, et
al: Modern concepts in the biology, diagnosis, differential
diagnosis and treatment of primary central nervous system lymphoma.
Leukemia. 25:1797–1807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thiel E, Korfel A, Martus P, Kanz L,
Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T,
Hundsberger T, et al: High-dose methotrexate with or without whole
brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase
3, randomised, non-inferiority trial. Lancet Oncol. 11:1036–1047.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
O'Brien P, Roos D, Pratt G, Liew K, Barton
M, Poulsen M, Olver I and Trotter G: Phase II multicenter study of
brief single-agent methotrexate followed by irradiation in primary
CNS lymphoma. J Clin Oncol. 18:519–526. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nabors LB, Portnow J, Ammirati M, Baehring
J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA,
Friedman A, et al: Central nervous system cancers, version 1.2015.
J Natl Compr Canc Netw. 13:1191–1202. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fraser E, Gruenberg K and Rubenstein JL:
New approaches in primary central nervous system lymphoma. Chin
Clin Oncol. 4:112015.PubMed/NCBI
|
|
41
|
Kim JE, Yoon DH, Kim S, Lee DH, Kim JH,
Yoon YH, Chi HS, Lee SW, Park CS, Huh J and Suh C: Relapse pattern
and prognostic factors for patients with primary central nervous
system lymphoma. Korean J Hematol. 47:60–66. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Prica A, Chan K and Cheung M: Combined
modality therapy versus chemotherapy alone as an induction regimen
for primary central nervous system lymphoma: A cost-effectiveness
analysis. Neuro Oncol. 16:1384–1391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Correa DD, Maron L, Harder H, Klein M,
Armstrong CL, Calabrese P, Bromberg JE, Abrey LE, Batchelor TT and
Schiff D: Cognitive functions in primary central nervous system
lymphoma: Literature review and assessment guidelines. Ann Oncol.
18:1145–1151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Batchelor TT: Primary central nervous
system lymphoma. Hematol Am Soc Hematol Educ Program. 2016:379–385.
2016. View Article : Google Scholar
|
|
45
|
Muirhead R, Murray EC, Bell SL, Stewart W
and James A: Is there a role for radiotherapy in the primary
management of primary central nervous system lymphoma? A
single-centre case series. Clin Oncol (R Coll Radiol). 25:400–405.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Swinnen LJ, O'Neill A, Imus PH, Gujar S,
Schiff D, Kleinberg LR, Advani RH, Dunbar EM, Moore D and Grossman
SA: Phase II study of rituximab given in conjunction with standard
chemotherapy in primary central nervous system lymphoma (PCNSL): A
trial of the ECOG-ACRIN cancer research group (E1F05). Oncotarget.
9:766–773. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hu Y, Feng FY, Shi YK, Zhou LQ, Gu DZ and
Wang QL: Primary central nervous system lymphoma: A report of 28
patients. Zhonghua Zhong Liu Za Zhi. 26:375–378. 2004.(In Chinese).
PubMed/NCBI
|
|
48
|
Zhang ET, Inman CB and Weller RO:
Interrelationships of the pia mater and the perivascular
(Virchow-Robin) spaces in the human cerebrum. J Anat. 170:111–123.
1990.PubMed/NCBI
|
|
49
|
Abrey LE, Ben-Porat L, Panageas KS,
Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta
M and DeAngelis LM: Primary central nervous system lymphoma: The
Memorial Sloan-Kettering Cancer Center prognostic model. J Clin
Oncol. 24:5711–5715. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Patrick LB and Mohile NA: Advances in
primary central nervous system lymphoma. Curr Oncol Rep. 17:602015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
DeAngelis LM, Yahalom J, Heinemann MH,
Cirrincione C, Thaler HT and Krol G: Primary CNS lymphoma: Combined
treatment with chemotherapy and radiotherapy. Neurology. 40:80–86.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bierman PJ: Surgery for primary central
nervous system lymphoma: Is it time for reevaluation? Oncology
(Williston Park). 28:632–637. 2014.PubMed/NCBI
|
|
53
|
Weller M, Martus P, Roth P, Thiel E and
Korfel A; German PCNSL Study Group, : Surgery for primary CNS
lymphoma? Challenging a paradigm. Neuro Oncol. 14:1481–1484. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Brastianos PK and Batchelor TT: Primary
central nervous system lymphoma: Overview of current treatment
strategies. Hematol Oncol Clin North Am. 26:897–916. 2012.
View Article : Google Scholar : PubMed/NCBI
|
